A study of more than 450,000 participants linked self-reported oral health issues with an increased risk of incident autoimmune diseases, though the investigators cautioned that the findings do not establish causality.
Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.
A real-world cohort found faster early skin responses with ixekizumab than with guselkumab or ustekinumab following secukinumab treatment failure, while all three biologics demonstrated favorable safety.